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Abstract
In this short review we provide a synopsis of recent developments in oxysterol research highlighting topics
of current interest to the community. These include the involvement of oxysterols in neuronal development
and survival, their participation in the immune system, particularly with respect to bacterial and viral
infection and to Th17-cell development, and the role of oxysterols in breast cancer. We also discuss the
value of oxysterol analysis in the diagnosis of disease.
Introduction
Oxysterols are oxygenated derivatives of cholesterol or its
sterol precursors, e.g. 7-dehydrocholesterol (7-DHC) or
desmosterol [1,2]. They are formed enzymatically in the
first steps of sterol metabolism and are intermediates in
the formation of the steroid hormones, bile acids and 1,25-
dihydroxyvitamin D3 [3]. Oxysterols may also be formed via
non-enzymatic routes by encounters with reactive oxygen
species [4,5], which provide a second pool of metabolites
which also include oxidized cholesterol molecules taken
from the diet [6]. A third pool may consist of oxidized
cholesterol molecules generated by the gut microflora and
taken up through the enterohepatic circulation. Although
once thought of as inactive metabolic intermediates, the
involvement of oxysterols in cholesterol homoeostasis, their
role as ligands to nuclear and G protein-coupled receptors
and their potential as easily measured biomarkers of disease
has enhanced interest in their biosynthesis, metabolism and
measurement. In this review we include in the family of
oxysterols the cholestenoic acids, C27 carboxylated forms of
cholesterol.
Oxysterols in neuronal development
survival
As the mammalian central nervous system (CNS) is rich in
cholesterol and oxysterols [7], it is perhaps not surprising
that oxysterols play a role in the nervous system. The most
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abundant oxysterol in brain is 24S-hydroxycholesterol (24S-
HC), present at a level of about 20–40 ng/mg in mouse and
man. This oxysterol plays a role as a cholesterol transport
molecule, crossing the blood brain barrier and passing from
brain to the blood stream for transport to the liver and
further metabolism [8]. 24S-HC is also a ligand to the liver
X receptors (LXRα and LXRβ) [9], both of which are
expressed in brain, and also to the endoplasmic reticulum
resident protein INSIG (insulin-induced gene) which upon
ligand binding anchors the transport protein SCAP (SREBP
cleavage-activating protein) along with its cargo, the pro-
form of the transcription factors SREBP (sterol regulatory-
element binding protein), in the endoplasmic reticulum
preventing its transport to the Golgi for activation [10].
The mature, or nuclear, forms of the SREBP proteins 1c
and 2 are transcription factors regulating the expression of
the biosynthetic enzymes of the fatty acid and cholesterol
synthesis pathways respectively [11]. It is likely that side-
chain oxysterols, like 24S-HC, are important for the fine
tuning of cholesterol biosynthesis, whereas cholesterol itself,
through direct binding to SCAP, is more important for the
coarse tuning of a negative-feedback mechanism [12,13].
In foetal development in mouse, cytochrome P450
(CYP) 46A1, the enzyme responsible for the metabolism
of cholesterol to 24S-HC, is weakly expressed until E18
[14], and instead 24S,25-epoxycholesterol (24S,25-EC) is a
dominating oxysterol (24S,25-EC, 0.3–0.4 ng/mg; cf. 24S-
HC, 0.03 ng/mg at E11.5) [15]. 24S,25-EC is an unusual
oxysterol in that it is synthesized via shunt pathways in
parallel to cholesterol synthesis rather from cholesterol
itself (Figure 1) [12]. Either, the enzyme squalene epoxidase
(SQLE), also known as squalenemonooxygenase (SM),
introduces one oxygen atom to squalene to give 2,3S-
oxidosqualene (squalene-2,3S-epoxide) followed by cyclisa-
tion by lanosterol synthase (LLS) to lanosterol for subsequent
cholesterol biosynthesis, or rather SQLE introduces a second
oxygen atom to squalene to give 2,3S:22S,23-dioxidosqualene
prior to cyclisation to 24S,25-epoxylanosterol, ultimately
leading to 24S,25-EC. A second pathway to 24S,25-EC
synthesis is from desmosterol in a CYP46A1 catalysed
reaction [16]. Interestingly, it has been shown that 24S,25-EC
and desmosterol, its parallel metabolite during cholesterol
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synthesis, are both reduced in concentration in brain from
Cyp46a1 knockout (Cyp46a1-/-) mice [17]. These data can
be explained by either, reduced expression of enzymes
of the cholesterol biosynthesis pathway in response to
removal of its export route through 24S-hydroxylation and
therefore enhanced negative feedback via cholesterol, SCAP
and SREBP, or alternatively, and perhaps in combination,
through elimination of the desmosterol to 24S,25-EC
pathway catalysed by CYP46A1. Unpublished data from the
authors and collaborators at Karolinska Institutet in Sweden
indicate that 24S,25-EC is more abundant in transgenic
mice overexpressing human CYP46A1, lending weight to
the hypothesis portending synthesis via this enzyme. This
pathway to 24S,25-EC synthesis may have importance in
developing brain where despite low expression of CYP46A1
desmosterol levels are high [18].
24S,25-EC is both a ligand to INSIG, thus involved in
regulation of cholesterol biosynthesis, and is also a potent
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0.
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ligand to the LXRs. Its comparative high level in developing
foetal mouse midbrain (0.39 ng/mg at E11.5) points to a
biological activity in this region [19]. Interestingly, midbrain
progenitors cells have reduced neurogenic capacity in
LxraLxrb double knockout mice (Lxra-/-Lxrb-/-), whereas
overexpression of Lxrs promotes midbrain dopaminergic
neurogenesis [20]. Recent studies have identified 24S,25-
EC as a midbrain LXR ligand promoting dopaminergic
neurogenesis in midbrain progenitor cells and embryonic
stem cell cultures [19]. These data suggest that LXR ligands
may be of value in cell replacement and regenerative therapies
for Parkinson’s disease, a disease in which dopaminergic
neurons are lost.
Adult Lxrb-/- mice show progressive accumulation of
lipids in brain and loss of spinal cord motor neurons
[21], indicating that LXRs are important for survival of
neurons in the adult. Besides oxysterols, cholestenoic acids
are also ligands to the LXRs [22,23] and there is an
expanding body of evidence indicating that cholestenoic
acids are synthesized in the CNS (Figure 2). Meaney et
al. [24] showed that there is a net export of 7α-hydroxy-
3-oxocholest-4-en-26-oic acid from human brain to the
circulation, in-part compensating for a net import of (25R)26-
hydroxycholesterol ((25R)26-HC) into brain from the
circulation [25]. Note, we use here systematic nomenclature
where hydroxylation at the terminal side chain of cholesterol
is on C-26 leading to 26-hydroxycholesterol (26-HC) which
may have 25R or 25S stereochemistry [26]. Unless stated
otherwise 25R stereochemistry is assumed. In much of the
literature (25R)26-HC is referred to 27-hydroxycholesterol
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0.
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(27-HC), presumably the 25R isomer. More recently, Crick
et al. [27] and Iuliano et al. [28] showed that 7α,(25R)26-
dihydroxycholest-4-en-3-one, a precursor of 7α-hydroxy-
3-oxocholest-4-en-(25R)26-oic acid in the pathway from
(25R)26-HC is similarly exported from human brain to
the circulation, and the authors group have identified low
levels (0.01 ng/mg) of 3β-hydroxycholest-5-en-(25R)26-oic
acid (3β-HCA) in mouse brain [29] and in collaboration with
investigators at Stanford University have identified this acid
and its down-stream metabolites 3β,7α-dihydroxycholest-
5-en-(25R)26-oic acid (3β,7α-diHCA) and 7α-hydroxy-
3-oxocholest-4-en-(25R)26-oic acid in porcine brain. All
of these cholesterol metabolites can also be found in
human cerebrospinal fluid (CSF) [29]. Using (25R)26-HC
as a starting substrate in the pathway to 7α-hydroxy-
3-oxocholest-4-en-(25R)26-oic acid the 7α-hydroxy group
is introduced by the enzyme CYP7B1. Mutations in
CYP7B1 leading to a defective oxysterol 7α-hydroxylase
enzyme result in the disease hereditary spastic paresis
type 5 (SPG5) [30]. Patients with this disease show upper
motor neuron degeneration, linking defective cholesterol
metabolism to motor neuron disorder. A second cholesterol
metabolic disorder, cerebrotendinous xanthomatosis (CTX)
can also present with motor neuron degeneration. In CTX
the (25R)26-hydroxylase enzyme, CYP27A1, is deficient,
resulting in deranged cholesterol metabolism. By profiling
the plasma and CSF of CTX and SPG5 patients we found that
both showed a reduced level of 3β,7α-diHCA, whereas SPG5
patients showed high levels of 3β-HCA. Further in vitro
and in utero studies in mouse identified 3β,7α-diHCA as a
neuroprotective molecule towards motor neurons whereas
3β-HCA was neurotoxic. The neuroprotective mechanism
is driven through LXR, indicating that specific cholestenoic
acids selectively work on motor neurons to regulate the
balance between survival and death [29].
Oxysterols in the immune system
25-Hydroxycholesterol (25-HC) is usually found at low
levels in biological samples, and there is often doubt if
it is formed enzymatically by cholesterol 25-hydroxylase
(CH25H) or through ex vivo oxidation during sample
handling and storage. However, activation of macrophages
through the Toll-like receptor (TLR) by lipopolysaccharide
or lipid A, mimicking bacterial infection, results in marked
up-regulation of CH25H and synthesis of 25-HC both
in mouse and man (Figure 3) [31,32]. Bauman et al.
[31] treated naı¨ve B-cells with nM concentrations of 25-
HC and found it suppressed IL-2 mediated stimulation
of B-cell proliferation, repressed activation of induced
cytidine deaminase expression, and blocked class switch
recombination, leading to markedly reduced IgA production.
They suggested that suppression of IgA class switching in B-
cells in response to TLR activation provides a mechanism
for negative regulation of the adaptive immune response
by the innate immune system. Blanc et al. [33] have found
that 25-HC is also produced by macrophages in response
to viral infection or interferon (IFN) stimulation and acts
as a paracrine inhibitor of viral infection. More recently,
Reboldi et al. [34] have shown that 25-HC acts as a mediator
in the negative-feedback pathway of IFN signalling on IL-
1 family cytokine production and inflammasome activity.
Ch25h-/- mice were found to show increased sensitivity
to septic shock, exacerbated experimental autoimmune
encephalomyelitis, a mouse model for multiple sclerosis,
and a stronger ability to repress bacterial growth [34].
7α,25-Dihydroxycholesterol (7α,25-diHC) is a down-stream
metabolite of 25-HC (Figure 3) and is also involved in the
immune response. Hannedouche et al. [35] and Liu et al.
[36] both identified 7α,25-diHC as a potent agonist of the
G protein-coupled receptor EBI2 (GPR183). 7α,25-diHC
was found to act as a chemoattractant for immune cells
expressing EBI2 by directing cell migration. Ch25h-/- mice
failed to position activated B-cells within the spleen to the
outer follicle and showed a reduced plasma cell response after
immune challenge [35].
The nuclear receptor RAR-related orphan receptor γ t
(RORγ t) is required for generating IL-17-producing CD4+
Th17 cells which are essential in host defence and may also
play pathogenic roles in autoimmune disease. CD4+ T-
cells comprise a heterogeneous group of effector T helper
(Th)-cells which function as the conductor, orchestrating
phagocytes and B-cells to effectively clear invading patho-
gens. Based on their cytokine-expression profile Th-cells
can be divided into various subtypes, including the pro-
inflammatory Th1 and Th17-cells and anti-inflammatory Treg-
cells. Multiple sclerosis, for example, is driven by an imbal-
ance between Th17, Th1 and regulatory Treg-cells. Soroosh et
al. [37] have identified 7β,26-dihydroxycholesterol (7β,26-
diHC), presumably the 25R-epimer, as a potent agonist
for RORγ t. 7β,26-diHC and its isomer 7α,26-diHC both
enhance the differentiation of murine and human IL-17-
producing Th17-cells in a RORγ t dependent manner [37].
Interestingly, Cyp27a1-/- mice, deficient in the (25R)26-
hydroxylase required to generate both 7β,26-diHC and
7α,26-diHC (Figure 3) show a significant reduction in IL-
17-producing cells, including CD4+ cells [37]. Soroosh et
al. using LC–MS based technology were able to identify
7β,26-diHC and 7α,26-diHC in Th17-cells as metabolic
products of exogenously added 7β-hydroxycholesterol
(7β-HC) and 7α-HC respectively. Furthermore, in vitro
differentiated Th17-cells were found to produce 7β,26-diHC
[37]. These data are particularly interesting as a sterol 7β-
hydroxylase enzyme has not been identified, although an
alternative route may be reduction of a 7-oxo intermediate
by the enzyme HSD11B1. In other studies, cholesterol
precursors, rather than oxysterols, have been suggested to
be RORγ t ligands. Hu et al. [38] found desmosterol as
a potent RORγ t agonist and showed that desmosterol
accumulates during Th17-cell differentiation as does its
sulfate ester, both serving as endogenous RORγ t agonists,
whereas Santori et al. [39] identified cholesterol precursor(s)
downstream of lanosterol but up-stream of zymosterol as
RORγ t ligands.
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0.
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Oxysterols as oestrogen receptor agonists
(25R)26-HC has been shown to be a selective oestrogen
receptor (ER) modulator [40]. Recently, it has been shown
by Nelson et al. [41] to be an ER ligand and to increase
ER-dependent growth in mouse models of breast cancer. In
addition, the expression of CYP27A1 was found to correlate
with tumour grade in breast cancer specimens, and in high
grade tumours CYP27A1 was expressed in tumour cells
and also tumour associated macrophages [41]. CYP7B1,
the enzyme which metabolizes (25R)26-HC to 7α,(25R)26-
diHC (Figure 2) was found to be elevated at the mRNA level
in several different human breast cancer data sets associated
with better survival outcome in luminal A types [41]. Luminal
A breast cancers generally express ER, so would be expected
to be effected by the oestrogenic activity of (25R)26-HC.
(25R)26-HC is also a ligand to the LXRs, and through this
interaction was found to promote breast cancer metastasis
[41]. It is not clear which other LXR ligands may have
similar effects. Importantly, the study by Nelson et al. [41]
links the oestrogenic and metastatic activity of (25R)26-
HC with hypercholesterolaemia which is a risk factor for
breast cancer in postmenopausal women. A second study
by Wu et al. [42] published at about the same time also
found (25R)26-HC to promote ER-positive breast cancer
growth. In the study of Wu et al. (25R)26-HC was found to
stimulate MCF-7 cell xenograph growth in mice, whereas in
ER+ breast cancer patients the level of 26-HC was found
to be higher in normal tissue than in similar tissue from
controls. Furthermore, the 26-HC level was higher in tumour
than healthy tissue. The increased 26-HC level in tumour
tissue was explained by reduced CYP7B1 expression [42].
Interestingly, neither 26-HC nor cholesterol levels in plasma
were found to be significantly elevated in cancer patients
compared with controls, but reduced expression of CYP7B1
was associated with poorer patient survival [42]. These two
studies by Nelson et al. [41] and Wu et al. [42] linking 26-
HC to ERα and breast cancer are likely to stimulate detailed
studies of the sterolome in breast and other cancers.
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0.
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Dendrogenin A a steroidal alkaloid
Dendrogenin A (DDA) is the product of the aminolysis
reaction between 5,6α-epoxycholesterol and histamine
(Figure 3) [43]. It has been found in mouse and human tissue
at pg/mg levels and in plasma at ng/ml concentrations [43].
Importantly DDA is not detected in cancer cell lines, and
its concentration in breast tumours is lower than controls,
suggesting anti-tumour properties. DDA triggers tumour re-
differentiation and inhibits tumour growth [43]. Interestingly,
DDA is an inhibitor of cholesterol epoxide hydrolase
(ChEH) the enzyme which hydrolyses 5,6-epoxycholesterols
(5,6-EC) to cholestane-3β,5α,6β-triol [43]. ChEH is a
dimer of 7-dehydrocholesterol reductase (DHCR7) and
3β-hydroxysteroid-8-7-isomerase (D8D7I), and acts as
a high affinity binding site for the anti-tumour drug
tamoxifen. Accumulation of 5,6-EC as a result of inhibition
of ChEH due to tamoxifen binding is likely to contribute
to tamoxifen’s anti-cancer pharmacology. The discovery
of DDA, a metabolite of cholesterol with anti-tumour
properties, contrasts to that of (25R)26-HC, a cholesterol
metabolite linked to promotion of breast cancer.
Oxysterols as markers of disease
Unsurprisingly, plasma oxysterol profiles are markers of
inborn errors of cholesterol metabolism, like CTX and SPG5,
and of cholesterol biosynthesis e.g. Smith–Lemli–Opitz
syndrome where DHCR7 is defective [44,45]. Perhaps more
surprisingly, bile acids, down-stream metabolites, are markers
of the lysosomal storage disease, Niemann–Pick type C
(NPC) [46]. In 2001 Alvelius et al. [46] reported an unusual
pattern of bile acids in urine from a patient with NPC. They
found elevated levels of 3β-hydroxy-5-ene bile acids with a
7-oxo or 7β-hydroxy group. More recently, Porter et al. [47]
reported elevated levels of 7-oxocholesterol and cholestane-
3β,5α,6β-triol in plasma from NPC1 patients. This has been
confirmed in numerous other studies and concentrations
of cholestane-3β,5α,6β-triol have also been found to be
elevated in NP type A and B patients [48]. The discovery of
effective biomarkers for NPC1 is particularly significant in
light of 2-hydroxypropyl-β-cyclodextrin showing promise
as an intrathecal medication [49].
Conclusions
Oxysterol research is currently gaining attention. The
involvement of oxysterols in neuroscience, immunity and
cancer highlights their importance in biology. Analysis of
oxysterols is still challenging and care must be taken to
avoid misinterpretation of data and confusion over isomer
identification.
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